Fluorescence Guided Surgery Systems Market Analysis & Forecast: 2026-2033
The fluorescence guided surgery systems market was valued at USD 146 Mn in 2026 and is forecast to reach a value of USD 428 Mn by 2033 at a CAGR of 16.2% between 2026 and 2033.
The fluorescence guided surgery systems market is experiencing strong growth due to the increasing prevalence of chronic disease across the globe and rise in usage of advanced imaging techniques. Moreover, increasing number of surgical procedures for target diseases is expected to boost growth of the market. However, factors such as stringent regulatory approval, side effects associated with fluoroscopy, and lack of skilled professionals expected to hamper growth of the global fluorescence guided surgery systems market.
|
Current Event |
Description and its Impact |
|
FDA Fast Track and Regulatory Approvals for Fluorescent Imaging Agents |
|
|
New Product Launches along with Technology Advancements in Surgical Imaging Platforms |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of type, the SPY system segment is expected to lead the market with 48% share in 2026, owing to its extensive adoption in clinical settings, strong brand recognition, and comprehensive technological integration. The SPY System, developed and broadly popularized by companies such as Stryker Corporation, has become synonymous with fluorescence-guided surgery owing to its proven efficacy in improving surgical outcomes across multiple specialties such as cardiovascular, plastic, and oncologic surgeries.
The system has very clear imaging and an easy-to-use design, so surgeons prefer it to reduce problems like leaks and tissue failures. Its major clinical validation, evidenced by numerous peer-reviewed studies highlighting advanced postoperative outcomes, adds to its dominant market presence.
In terms of surgery, the open surgery segment is expected to hold 60% share of the market in 2026. Open Surgery contributes the highest share in the market, owing to multiple factors that reinforce its dominance. Open surgery, as a traditional and widely practiced surgical approach, remains the preferred method in a considerable number of clinical scenarios owing to its accessibility and versatility when operating on complex or extensive anatomical structures.
Open surgery lets surgeons see and reach the area easily, helping them use special imaging agents that make the operation clearer. Fluorescence guidance in open surgery improves real-time delineation of vital structures such as blood vessels, lymph nodes, as well as tumors, directly impacting surgical outcomes by reducing inadvertent damage and improving resection margins.
In terms of application, the Cancer surgeries segment is projected to account for 66.4% share of the market in 2026. This is due to the critical need for precision in oncological procedures, as FGS allows surgeons to clearly distinguish cancerous tissues from healthy tissues in real time.
For instance, OECD data shows that age‑standardized cancer mortality rates have decreased from 204 deaths per 100,000 population in 2019 to 191 deaths per 100,000 in 2023, highlighting the ongoing global emphasis on improving cancer outcomes.
To learn more about this report, Download Free Sample
North America is expected to dominate the fluorescence guided surgery systems market with 48% share in 2026, due to multiple region-specific factors that establish the United States and Canada as pivotal hubs of medical innovation and healthcare infrastructure. A dominant driver in this region's leadership is its highly developed healthcare system integrated with utilization adoption of advanced surgical technologies.
For instance, in March 2026, Olympus Corporation launched the VISERA ELITE™ III surgical imaging system in the U.S. This system aids surgeons see better during operations, makes surgery faster and easier, and can be used in different types of surgeries. It is the third major product developed by SONY Olympus Medical, a joint venture started in 2013.
Asia Pacific is expected to exhibit the fastest growth, propelled by a combination of increasing healthcare infrastructure investments, growing surgical volumes, and rising awareness about minimally invasive surgical technologies. Countries like China, India, Japan, South Korea, and Australia have experienced rapid modernization of their healthcare delivery ecosystems that directly adds to the burgeoning demand for fluorescence-guided surgery solutions.
For instance, in December 2025, HKU used a new infrared fluorescence imaging system for the first time in patients. This helps surgeons see blood flow during esophagus surgery.
The U.S. subsegment contributes the highest share in the Fluorescence Guided Surgery (FGS) Systems market in North America, owing to its advanced healthcare infrastructure, extensive adoption of cutting-edge surgical technologies, as well as favorable reimbursement policies that encourage innovation in surgical care. The U.S. healthcare system is marked by a concentration of world-renowned medical institutions and research centers that actively engage in the development as well as clinical implementation of fluorescence imaging techniques during surgeries.
For instance, in July 2025, Vanderbilt Health is using fluorescence imaging to help surgeons see nerves more clearly during head and neck surgery. The study sought to evaluate the safety of bevonescein, a synthetic peptide-dye conjugate thought to be applicable for intraoperative nerve-specific fluorescence imaging.
China contributes the highest share in the Fluorescence Guided Surgery (FGS) Systems market in the region owing to its vast healthcare infrastructure developments, increasing governmental support for advanced surgical technologies, and a growing volume of surgical procedures that rely on imaging guidance. China's commitment to modernizing its healthcare delivery, particularly in oncology and minimally invasive surgeries, has significantly driven the adoption of fluorescence-guided systems.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 146 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 16.2% | 2033 Value Projection: | USD 428 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Irillic Pvt. Ltd., Karl Storz, PerkinElmer, Curadel LLC, Gentige (Fluoptics), OnLume Inc., Medtronic PLC, Hamamatsu Photonics KK, Stryker Corporation, Shimadzu Corporation, and Olympus Corporation (Quest Medical Imaging), among others |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The increasing adoption of minimally invasive surgical (MIS) procedures is significantly driving the growth of the Fluorescence Guided Surgery (FGS) Systems market by enhancing surgical precision, reducing patient recovery time, and improving overall outcomes. MIS techniques, such as laparoscopic and robotic-assisted surgeries, rely heavily on advanced imaging technologies to compensate for the limited visual field and access compared to traditional open surgeries.
The rising prevalence of cancer and other chronic diseases is significantly propelling the demand for Fluorescence Guided Surgery (FGS) systems globally. Cancer remains one of the leading causes of death worldwide, with the World Health Organization (WHO) reporting approximately 10 million cancer-related deaths in 2020 alone, making it the second highest cause of mortality after cardiovascular diseases. The complexity of cancer surgeries, especially in cases involving brain tumors, head and neck cancers, and breast cancer, demands highly precise resection techniques to ensure maximal removal of malignant tissues while sparing healthy structures.
The development of novel fluorescent probes and contrast agents represents a significant opportunity within the Fluorescence Guided Surgery (FGS) Systems market, primarily due to their potential to drastically enhance surgical precision and patient outcomes. Traditional fluorescence agents often face limitations such as low specificity, rapid photobleaching, and suboptimal tissue penetration, which constrain their utility in complex surgical environments.
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
